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A B S T R A C T
Invasive fungal infections cause approximately 1.5 million deaths per year worldwide and are a growing threat
to human health. Current anti-fungal therapies are often insuﬃcient, therefore studies into host-pathogen in-
teractions are critical for the development of novel therapies to improve mortality rates. Myeloid cells, such as
macrophages and dendritic cells, express pattern recognition receptor (PRRs), which are important for fungal
recognition. Engagement of these PRRs by fungal pathogens induces multiple cytokines, which in turn activate T
eﬀector responses. Interleukin (IL)-12 family members (IL-12p70, IL-23, IL-27 and IL-35) link innate immunity
with the development of adaptive immunity and are also important for regulating T cell responses. IL-12 and IL-
23 have established roles during anti-fungal immunity, whereas emerging roles for IL-27 and IL-35 have recently
been reported. Here, we discuss the IL-12 family, focusing on IL-27 and IL-35 during anti-fungal immune re-
sponses to pathogens such as Candida and Aspergillus.
1. Introduction
Interleukin (IL)-12 family members (IL-12p70, IL-23, IL-27 and IL-
35) link innate immunity with the development of adaptive immunity
[1]. They are important in regulating T cell responses and while
structurally similar, they display diﬀerent functional activities. IL-12
and IL-23 are both considered to be pro-inﬂammatory [2,3]. IL-12
predominantly favors T helper (Th)1 cell diﬀerentiation [4–6], whereas
IL-23 enhances Th17 responses and is involved in the activation and
expansion of memory T-cells [7,8]. IL-27 has both pro- and anti-in-
ﬂammatory properties and is a potent T cell immunomodulator. IL-27
was originally reported to enhance Th1 cell diﬀerentiation [9,10].
However, subsequent studies highlight more nuanced roles linked with
suppression of adaptive immunity, where IL-27 inhibits IL-2 signaling,
antagonizes Th17 cells and promotes regulatory T cells (Tregs) re-
sponses [11–16]. Lastly, IL-35 induces Tregs and regulatory B cells
(Bregs) and suppresses T cell responses [17]. IL-12 and IL-23 have es-
tablished roles during anti-fungal immunity [7,18–29] and new roles
for IL-27 and IL-35 have recently been reported [20,23,30]. Im-
portantly, the new roles reported for IL-27 as a regulatory cytokine
emerged from infection studies suggesting that IL-27 may also have
important roles in fungal control. This review will focus on the role of
these newer family members during fungal infections, such as Candida
and Aspergillus infections.
Candida species (spp). cause various types of disease, from mucosal
infections (eg. oral and vaginal thrush) to life threatening invasive
candidiasis. Candida spp. bind various Pattern Recognition Receptors
(PRRs) such as C-type lectin-like receptors (CLRs) including Dectin-1,
Toll-like receptors (TLRs) and Nucleotide-binding Oligomerisation do-
main-like receptors (NLRs) on myeloid cells [31]. This induces multiple
cytokines, which in turn activate Th1 and Th17 responses [32–38]. The
production of IFN-γ by Th1 cells has been shown to be crucial in the
control of systemic candidiasis in a murine model [21,39–41]. Whereas,
the Th17 response protects against oropharyngeal and mucocutaneous
models of candidiasis while increasing disease susceptibility in a gas-
trointestinal model [7,29,42,43].
Aspergillus fumigatus is an airborne fungus that causes various types
of disease including invasive pulmonary aspergillosis (IPA) and allergic
bronchopulmonary aspergillosis (ABPA). An important role of the host
immune response is to limit spore germination and restrict hyphal in-
vasion. Spore swelling, the ﬁrst step of germination, exposes fungal li-
gands that bind to CLRs and TLRs resulting in inﬂammatory cytokine
production [44,45]. This then induces a Th1 response and a much
smaller Th17 response in a pulmonary infection model [25,46] whereas
a Th2 response is induced in an allergic model of disease [47,48].
The T cell responses mediated by these diﬀerent pathogens (Candida
and Aspergillus) are likely controlled by the ligands exposed on their cell
surface and by the environment (e.g. systemic, mucosal, pulmonary) of
the infection. The yeast form of C. albicans expresses mannans on the
cell surface and β-glucans are rapidly exposed at bud scars whereas
dormant Aspergillus conidia are covered in a rodlet layer that initially
hides β-glucans from the immune system [44,49,50]. Mannans present
on the yeast form of C. albicans have been shown to induce IL-1β and IL-
23 in a Dectin-2 dependent manner [37]. Additionally, both yeast and
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hyphal forms of C. albicans induced Dectin-2-dependent Th17 diﬀer-
entiation in vitro and Il17a deﬁcient mice were more susceptible to
systemic infection with C. albicans [37]. Further to this, dendritic cells
(DCs) activated by Dectin-1 engagement by curdlan, a β-glucan pre-
paration, demonstrated Th17 cell diﬀerentiation of CD4+ T cells in
vitro, and the use of curdlan as an adjuvant in vivo, promoted both Th17
and Th1 responses [34]. We have previously demonstrated diﬀerences
in T cell diﬀerentiation in vitro and in vivo. Heat killed yeast pre-
dominantly induced Th17 diﬀerentiation in vitro, whereas, mice sys-
temically infected with C. albicans displayed a Th1-biased response in
vivo [19], therefore the environment is also important for determining T
cell bias. In the context of A. fumigatus infections, Th1 and Th17 CD4+
T cells are driven via TLR/MyD88 and Dectin-1 respectively. TLR2 and
TLR4 recognise A. fumigatus conidia [51], whereas Dectin-1 recognises
later morphological forms such as swollen conidia and early germlings
[44]. It is possible that the TLRs initiate a Th1 response to A. fumigatus
and then Dectin-1 induces the Th17 response once germination of A.
fumigatus is further underway. As C. albicans and A. fumigatus engage
diﬀerent combinations of PRRs, interactions between these PRRs likely
dictate the balance between Th1 and Th17 responses to these two pa-
thogens.
2. IL-12 family cytokines
2.1. Structure
IL-12 family cytokines consist of four heterodimeric proteins (Figs. 1
and 2), which are mainly produced by myeloid cells. This has been
extensively reviewed elsewhere [22,52–57]. IL-12 is made up of 2
subunits, IL-12p35 and IL-12p40, which together form active IL-12p70.
IL-12p70 is a very potent activator of Th1 cell responses [4,5]. IL-12p40
is also expressed and secreted as a monomer and a homodimer [58,59].
The p40 monomer has no biological function whereas the homodimer is
an antagonist of IL-12p70 by competitively binding the IL-12R [60].
The IL-12p40 homodimer enhances alloantigen-speciﬁc Th1 develop-
ment suggesting similar functional activity to IL-12p70 under certain
conditions [61]. IL-23 is composed of IL-23p19 and IL-12p40 (shared
with IL-12p70). IL-23 is tightly regulated and is functionally distinct
from IL-12. IL-27 is a heterodimer made up of IL-27p28 and Epstein
Barr virus induced gene 3 (EBI3) subunits [10,62]. IL-27p28 has also
been shown to be expressed as a monomer, which can inhibit IL-6, IL-27
and IL-11 signalling through the common gp130 signalling receptor
[63,64]. IL-27 modulates pro- and anti-inﬂammatory signaling
[65–67]. IL-35 consists of the EBI3 subunit (shared with IL-27) and the
IL-12p35 subunit (shared with IL-12) [68]. IL-35 promotes Treg re-
sponses and suppresses Th1 and Th17 responses. Treg cells deﬁcient in
either Ebi3 or Il12a (IL-12p35) display a reduced ability to inhibit ef-
fector T cell proliferation [69–72].
2.2. Signaling
IL-12 binds to IL-12Rβ1 and IL-12Rβ2 and signals via Janus asso-
ciated kinase 2 (JAK2) and tyrosine kinase 2 (Tyk2) to activate various
signal transducer and activator of transcription (STAT) family members
[3,73] (Fig. 1). Patients with defective IL12B or IL12RB1 [74] and cells
from mice deﬁcient for Tyk2 or STAT4 showed reduced IFN-γ produc-
tion in T cells and natural killer (NK) cells [75–77]. IL-23 binds IL-
12Rβ1 and IL-23R [78,79] and signals in a similar manner to IL-12
[79,80] (Fig. 1). JAK2 and Tyk2 constitutively associate with IL-23R
and IL-12R-β1 chains respectively [79]. IL-23 activated STAT3 and
STAT4 is critical for IL-17 induction from Th17 cells [81,82]. The IL-
23R and IL-12R-β1 chains alone lack intrinsic enzymatic activity
[2,3,79,83].
IL-27 signals through IL-27Rα (WSX-1/TCCR) paired with glyco-
protein (gp)130 [84] (Fig. 1). IL-27 can bind WSX-1 with low aﬃnity in
the absence of gp130, however both IL-27R subunits are required for
eﬀective signal transduction [10,84]. IL-27 signaling activates various
JAK and STAT family members in a cell-speciﬁc manner. For example,
IL-27 activates both STAT1 and STAT3 in naïve CD4+ T cells but in
fully active T cells only STAT3 activation is retained [85]. IL-35 sig-
naling is unconventional as it utilizes diﬀerent receptor combinations
including IL-12Rβ2 and gp130 homodimers and heterodimers (Fig. 2).
STAT1 and/or STAT4 are activated depending on which receptor
homodimer/heterodimer is engaged. In B cells IL-35 signals through IL-
12Rβ2 and WSX-1 to activate STAT1 and STAT4. More work is required
to fully understand IL-35 signaling downstream of the diﬀerent
homodimers or heterodimers [17,86].
3. IL-12 family cytokines in anti-fungal host defense
3.1. IL-12
IL-12 is induced by microbial products in monocytes, macrophages
and DCs and acts on NK and T cells to induce IFN-γ. IFN-γ in turn ac-
tivates monocytes and macrophages to induce further IL-12 production
[87]. This positive feedback mechanism helps protect against certain
pathogens that induce low IL-12 levels [88]. Deﬁciency of IL-12 or IL-
12R genes leads to impaired cell mediated immunity and enhanced
disease susceptibility [89–92]. We will only brieﬂy discuss the role of
IL-12 during Candida infections as this has been reviewed elsewhere
[22,93].
Several C. albicans infection experiments have been performed in
mice deﬁcient in diﬀerent components of the IL-12 family (Table 1).
However, due to subunit sharing between diﬀerent family members,
interpretation of these results is rather complex. Overall, IL-12 appears
to be important during systemic infection but less important during
mucocutaneous infections. Il12p40-/- mice were susceptible to oral in-
fection with C. albicans, however, this was mainly attributed to IL-23
and Th17 responses [29]. Interestingly, Il12p35-/- mice demonstrated
disseminated infection following oral infection with C. albicans sug-
gesting that while IL-12 is not overly important in the local response
during an oral infection, it controls systemic dissemination [29]. In
addition, Il12p35-/- and IFN-γ-/- mice displayed enhanced susceptibility
to systemic infection with C. albicans [7,39–41], indicating an im-
portant role for IL-12/Th1 responses during systemic infection.
Il12p40-/- mice displayed variable susceptibility to systemic infection in
diﬀerent studies [7,26,94]. Additionally, in a mouse model where
mannoproteins from the fungal pathogen Cryptococcus neoformans were
shown to protect against systemic C. albicans infection, this protective
response was reversed upon IL-12 blockade [95]. Further, when IL-12
was fused to enolase (a C. albicans antigen) and administered during
systemic infection with C. albicans, mice demonstrated increased sur-
vival and decreased fungal burden in their kidneys [27]. However,
administration of IL-12 during systemic infection increased disease se-
verity due to IFN-γ mediated pathology [96]. These data suggest that
while IL-12 and IFN-γ are important for controlling systemic infections
with C. albicans, this response needs to be ﬁnely tuned for optimal
fungal clearance while minimising pathology.
The importance of IL-12 has also been demonstrated during A. fu-
migatus infections. Human DCs infected with A. fumigatus induced IL-
12p70 production and promoted IFN-γ production from CD4+ T cells
[20]. Rivera et al. [25] showed that Th1 and Th17 responses are in-
duced during an in vivo model of A. fumigatus lung infection. The au-
thors showed that TLR and Dectin-1 pathways modulate the balance
between Th1 and Th17 populations by controlling production of IL-12
family members. In addition, IL-12 has been shown to induce human
monocytes to damage A. fumigatus hyphae via an oxidative burst re-
sponse in an IFN-γ-independent manner [97].
During an in vivo infection model with A. fumigatus, Cenci et al. [98]
compared the immune response of resistant (intact DBA/2 mice) and
susceptible (leukopenic DBA/2 mice) mice. Interestingly, the authors
demonstrated that resistant mice produced high levels of IL-12, TNF
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and IFN-γ while susceptible mice produced an IL-10 and IL-4 skewed
response. In addition, immunosuppressed Il12p40-/- and Ifng-/- mice
were more susceptible to invasive pulmonary aspergillosis [99]. In
agreement with this, Nagai et al. [100] showed that administration of
IFN-γ protected mice from invasive aspergillosis. Furthermore, Delsing
et al. [101] showed that adjunctive therapy with IFN-γ and an anti-
fungal drug partially restored immune function in patients with in-
vasive Candida and/or Aspergillus infections indicating that further
clinical studies are warranted to fully determine the potential clinical
beneﬁts of IFN-γ therapy during invasive fungal infections.
3.2. IL-23
IL-23 is involved in the maintenance of Th17 cells and the activation
of memory T-cells [78,102]. It induces CD4+ Th17 cells to produce IL-
17 and IL-22 [80,103–105]. IL-17A is a proinﬂammatory cytokine that
promotes neutrophil recruitment via upregulation of other cytokines
and chemokines [106]. While the IL-23-IL-17 pathway is important for
protective responses against infection, it can also contribute to auto-
immunity and increased pathology [107,108]. IL-23 is also important
for regulation of innate lymphocyte cells (e.g. innate lymphoid, NK,
NKT and γδ T-cells [109]).
C. albicans induces IL-23p19 and/or IL-23 in cultured macrophages
and DCs and at sites of inﬂammation during infection [19,24]. Inter-
estingly, human monocyte derived DCs produced IL-23 when chal-
lenged with C. albicans hyphae, whereas C. albicans yeast induced IL-12
production and IL-23 was only produced with high concentrations of
yeast [110]. This suggests that the hyphal form of C. albicans triggers
the Th17 response in vivo.
During systemic infection with C. albicans, IL-23 was dispensable,
however the IL-23/Th17 pathway is important during chronic mucco-
cutaneous candidiasis (CMC) [7]. Il23p19-/-, and Il17ra-/- mice were
more susceptible to oral C. albicans infection [29]. However, Yano et al.
(2012) found that fungal burden and S100A8/S100A9 alarmin-medi-
ated neutrophil recruitment was normal in Il23p19-/-, Il17ra-/- and
Il22-/- mice in a mouse vaginal infection model suggesting that the
vaginal alarmin S100 response is independent of the IL-23/Th17 axis
[111]. In contrast, several other studies have found important roles for
Th17 cells, IL-17 and IL-22 in protecting patients against CMC
[29,43,112]. Patients with impaired Th17 and Th17-associated cyto-
kines due to mutations in genes such as STAT3 (hyper IgE syndrome,
[113,114]), IL-17RA [115], IL-17F [115], ACT1 [116], STAT1
[117,118], AIRE [119,120], IRF8 [121], CARD9 and DECTIN-1
[122–124] are prone to CMC. In addition, two Mexican patients with a
mutation in IL12RB1, suﬀered from infections with Baccille Calmette-
Guérin (BCG) and C. albicans and they both died early at ages 4 and 16
Fig. 1. IL-12, IL-23 and IL-27 cytokines and their receptors. (A) IL-12 is a heterodimeric cytokine made up of a light chain IL-12p35 and a heavy chain IL-12p40. The
IL-12 receptor is made up of IL-12Rβ1 and IL-12Rβ2 and signals through Tyk2 and JAK2 to activate STAT1, 3, 4 and 5. STAT4 induces nuclear translocation of IFN-γ.
(B) The IL-12p40 component of IL-23 can dimerise with IL-23p19 to form IL-23. The IL-23 receptor is comprised of IL-12Rβ1 and IL-23R and signals through Tyk2
and JAK2 to activate STAT1, 3, 4 and 5. STAT3 induces nuclear translocation of the IL-23R, IL-17A and IL-22; and STAT4 induces nuclear translocation of IL-17A/F.
(C) IL-27 is composed of EBI3 and IL-27p28. IL-27 binds a receptor composed of gp130 and IL-27Rα and signals through JAK1, Tyk2 and JAK2 to activate STAT1, 2,
3, 4 and 5. STAT1 induces nuclear translocation of Tbet and inhibition of GATA3; and STAT3 induces nuclear translocation of IL-10.
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[125]. Furthermore, in an international study of 141 patients, 23% of
patients lacking IL12RB1were found to suﬀer from CMC [126]. How-
ever, as both IL-12 and IL-23 signal through IL-12Rβ1, this could be due
to a lack of responsiveness to either cytokine. IL-23 and IL-6 were
detected in vaginal secretions from women infected with vaginal can-
didiasis [24,127]. Additionally, healthy PBMCs stimulated with C. al-
bicans induced a Th17 response demonstrating that Th17 cells are in-
volved in the defense against C. albicans [128]. Furthermore, reduced
Fig. 2. IL-35 cytokines and their receptors. IL-35 is a heterodimeric cytokine made up of EBI3 (shared with IL-27) and IL-12p35 (shared with IL-12). gp130 couples
with IL-12Rβ2 to form the IL-35 receptor complex and signals through JAK1 and JAK2 to activate STAT1, 3 and 4. STAT-1-STAT4 form a heterodimer to induce
nuclear translocation and induction of IL-12α/p35 and EBI3. Additionally, homodimers of gp130 or IL-12Rβ2 have been shown to elicit a partial IL-35 induced
response in T cells [86], and IL-12Rβ2 can also couple with IL-27Rα to also form an IL-35 receptor complex in B cells [17].
Table 1
Eﬀects of diﬀerent Candida and Aspergillus infections on Il12p40-/-, Il12p35-/-, Il23p19-/- and Il27ra-/- mice.
Genotype Pathogen Outcome References
Il12p40-/- C. albicans Susceptible to oral challenge Farah et al. [26]
C. albicans Reduced fungal burden during systemic challenge (1, 3 days post infection) but increased fungal burden following re-
infection
Mencacci et al. [94]
C. albicans No eﬀect during systemic challenge Netea et al. 2003 [170]
C. albicans No eﬀect during systemic challenge (5 days post infection) Farah et al. 2006 [26]
C. albicans Increased fungal burden during gastrointestinal challenge (3, 10 days post infection) Zelante et al. [7]
C. albicans Susceptible to cutaneous challenge Kagami et al. [112]
C. albicans Increased fungal burden during gastrointestinal challenge Mencacci et al. [94]
A. fumigatus Increased fungal burden during IPA in immunosuppressed mice Cenci et al. [99]
A. fumigatus Reduced fungal burden during IPA Zelante et al. [7]
Il12p35-/- C. albicans Systemic dissemination during oral challenge Conti et al. [29]
C. albicans Susceptible to gastrointestinal challenge Zelante et al. [7]
C. albicans No eﬀect during cutaneous challenge Kagami et al. [112]
A. fumigatus Reduced fungal burden during IPA Zelante et al. [7]
Il23p19-/- C. albicans Susceptible to oral challenge Conti et al. [29]
C. albicans No eﬀect during gastrointestinal challenge Zelante et al. [7]
C. albicans No eﬀect during vulvovaginal challenge Yano et al. [111]
C. albicans Susceptible to cutaneous challenge Kagami et al. [112]
A. fumigatus Reduced fungal burden during IPA Zelante et al. [7]
Il27ra-/- C. albicans No signiﬁcant eﬀect during systemic challenge Patin et al. [30]
C. parapsilosis Enhanced fungal clearance and reduced fungal burden in the kidneys during systemic challenge (6 weeks post infection) Patin et al. [30]
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Th17 responses have been reported in human PBMCs stimulated with C.
albicans from patients with hyper IgE syndrome, demonstrating that
Th17 cells play an important role in the defense against C. albicans
[113]. These data indicate a protective role for the IL-23/Th17 pathway
during C. albicans infection, however, heightened IL-17 and IL-23 re-
sponses can also negatively regulate Th1 responses to C. albicans re-
sulting in increased inﬂammation and susceptibility to candidiasis [7].
Therefore, similar to IL-12 and IFN-γ, the IL-23/Th17 response needs to
be tightly controlled. Th17 cells express IL-10Rα and IL-10 signalling
has been shown to control IL-17A producing CD4+ T cells in a colitis
model [129], suggesting that IL-10 may be an important regulator of IL-
23/Th17 responses during anti-fungal immunity.
Studies have demonstrated a role for the IL-23/Th17/IL-17 pathway
during A. fumigatus infection [7,130]. Il12p40-/-, Il12p35-/- and
Il23p19-/- mice displayed reduced fungal burden in the lungs of A. fu-
migatus infected mice, indicating that a heightened IL-23/Th17 re-
sponse is associated with susceptibility [7]. However, Dectin-1 and
TLR9 deﬁcient mice displayed reduced IL-23, IL-17A and/or IL-22 re-
sponses and increased fungal burden in the lungs of A. fumigatus chal-
lenged mice, indicating that the IL-17 pathway is involved in a pro-
tective response to A. fumigatus [131,132]. In contrast, an
immunopathogenic role for Dectin-1 and IL-22 has been shown during
chronic fungal allergy [104], once again demonstrating the importance
for tight regulation of these pathways. IL-17 has been shown to inhibit
neutrophil mediated killing of A. fumigatus and in vivo clearance [7].
Th1 cells, Treg cells, and Th17 cells are all important in producing both
an inﬂammatory and anti-inﬂammatory response against A. fumigatus
[7,48,133]. The balance between Th17 cells and Treg cells has been
suggested to be important in determining whether commensal C. albi-
cans causes infection and the same could be true for Aspergillus infec-
tions [134,135].
3.3. IL-27
The ability of IL-27 to regulate T cell responses has been reviewed
elsewhere [136,137]. Brieﬂy, IL-27 was shown to enhance in vitro Th1
cell diﬀerentiation [138]. However, more recently, anti-inﬂammatory
properties of IL-27 have been discovered. IL-27 has been shown to in-
hibit T cell responses by negatively regulating IL-2 signaling and by
inducing IL-10 [11,12,66,139–142]. IL-10 has been shown to inhibit
both CD4+ and CD8+ T cell responses [134,143]. Additionally, a role
in inhibiting Th17 cell diﬀerentiation has been demonstrated to protect
against Th17 associated disease, such as encephalomyelitis [11–14].
Th17 cells in encephalomyelitis promotes the development of ectopic
lymphoid structures in the central nervous system [144]. Interestingly,
IL-27 inhibits the development of ectopic lymphoid structures in in-
ﬂamed tissues [145]. These functions of IL-27 help protect against T-
cell driven pathology. IL-27 has shown contrasting eﬀects on regulatory
T cells. It has been shown to promote Treg growth and survival at sites
of infection [16] but also to indirectly inhibit Treg development by
inhibiting IL-2 production [15,16].
IL-27 has been reported to be involved in the immune response to
various pathogens including Trypanosoma cruzi [146], Leishmania major
[147–149], Mycobacteria tuberculosis [11] and Toxoplasma gondii
[12,14,150]. In addition, a limited number of studies reviewed here,
have recently examined the role of IL-27 in response to fungal patho-
gens. The ﬁrst report in a fungal model demonstrated that EBI3 levels
were signiﬁcantly induced in human monocyte derived DCs following
stimulation with A. fumigatus while IL27 levels only showed a slight
increase, demonstrating that A. fumigatus-induced IL-27 production is
minimal [20]. Indeed, it is possible that the increased EBI3 levels could
actually reﬂect IL-35 induction rather than IL-27 production, as human
monocyte derived tolerogenic DCs express and produce IL12A and EBI3
[151], although this remains to be determined in a fungal model.
However, in a later study these authors went on to show that IFN-β
treated DCs challenged with A. fumigatus resulted in increased IL27
mRNA levels, IL-12p70 production and increased expression of CD86
and CD83 [152]. While it is well established that IFN-β induces IL-27
[153], this report describes a new role for A. fumigatus in IL-27 pro-
duction [152]. Further, DCs stimulated with IFN-β and challenged with
A. fumigatus resulted in increased Th1-mediated IFN-γ production
[152]. This suggests that IFN-β could be used as a possible therapy to
enhance a beneﬁcial Th1 response during infection with A. fumigatus.
Type 1 regulatory T cells (Tr1) are instrumental in protecting
against Th1/Th17-mediated autoimmunity in mice and reactions to
common allergens in humans [154,155], and may also play an im-
portant role during A. fumigatus infections [156]. Tr1 cells are Foxp3-
regulatory T cells that produce high IL-10 levels and suppress T cell
expansion in vitro and in vivo [157]. Bedke et al. [156] identiﬁed Crf-1/
p41-speciﬁc latent associated peptide+ and IL-10+ Tr1 cells in healthy
humans and in mice following vaccination with an Aspergillus peptide
(Crf-1/p41) and zymosan. In agreement with previous studies
[158,159], Tr1 cell diﬀerentiation in vivo was found to be dependent on
the aryl hydrocarbon receptor, c-Maf and IL-27. These data indicate
that IL-27 plays a role in maintaining anti-fungal immune homeostasis
via induction of Tr1 cell diﬀerentiation [156].
Several inﬂammatory cytokines/molecules, such as lipopoly-
saccharide (LPS) [10,22,160,161], IL-1β [162], Poly(I:C) [161] and
IFN-β [152,153,163], have been reported to induce IL-27 as a protec-
tive response to prevent excess inﬂammation. Interestingly, increased
expression of IL27 and EBI3 has been shown in THP-1 cells challenged
with heat killed C. albicans compared with LPS [22]. In contrast, IL-27
production was reduced in the RAW264.7 macrophage cell line when
treated with bakers yeast (saccharomyces cerevisiae)-derived β-glucan
(BBG) [160]. In addition, we showed that β-glucan alone does not in-
duce IL-27 in bone marrow derived macrophages (BMDMs) [30]. We
also showed that select Candida spp. induce IL-27 production, such as C.
parapsilosis, C. glabrata and C. tropicalis but not C. albicans. IL-27 pro-
duction by C. parapsilosis was dependent on phagocytosis, TLR7/MyD88
and nucleotide-binding oligomerisation domain-containing protein
(NOD)2 signaling. Further, C. parapsilosis induced IFN-β production,
which then signaled through the IFN-α/β receptor (IFNAR) and STAT1/
2 to induce IL-27 (Fig. 3). Interestingly, while we found that C. albicans
did not induce IL-27, likely due to the absence of IFN-β induction, it
also actively blocked C. parapsilosis-induced IL-27 via a soluble med-
iator [30]. This soluble mediator has yet to be identiﬁed, but it is
tempting to speculate that BBG might induce the same soluble mediator
to block IL-27 production [160]. However, it is interesting to note that
live C. albicans blocked C. parapsilosis-induced IL-27 in mouse BMDMs
[30] while heat killed C. albicans enhanced LPS-induced IL-27 in the
human THP-1 cell line [22]. These discrepancies could be due to dif-
ferences in mouse vs human IL-27/cells or due to exposure of diﬀerent
ligands on live vs heat killed C. albicans and requires further study to
unravel these diﬀerences.
Similar to infections with other pathogens such as M. tuberculosis, P.
berghei and T. gondii [11,164], we demonstrated improved clearance of
systemic C. parapsilosis infection in WSX-1 (Il27ra) deﬁcient mice. This
was accompanied by increased IFN-γ and IL-17 T cell responses in ad-
dition to increased serum pro-inﬂammatory cytokine levels [30]. While
we observed improved fungal clearance and only a modest increase in
inﬂammation, other groups have shown improved pathogen clearance
in WSX-1 deﬁcient mice accompanied by fatal organ pathogenesis due
to highly elevated pro-inﬂammatory responses [11,12,164]. Interest-
ingly, some studies showed that organ pathology could be prevented by
depleting CD4+ T cells but not CD8+ T cells [12,164]. As C. parapsilosis
induced a CD8+ T cell biased response rather than a CD4+ T cell re-
sponse, this could account for the improved fungal clearance without
inducing fatal organ pathology [30]. These data suggest that blocking
IL-27 during infection with C. parapsilosis could have therapeutic ben-
eﬁts.
In this review, it has already been mentioned that Th17 cells, IL-17,
IL-22 and IL-23 cytokines have important role in protecting patients
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against CMC [7,24,29,43,112]. Patients with a gain of function muta-
tion in STAT1 have higher susceptibility to Candida infections [165].
Further, increased STAT1 function showed increased IL-27, IFN-γ and
IFN-α production but reduced IL-17 responses [165–167]. In a separate
study, it has been reported that reduced IFN-γ and IL-27 responses from
impaired STAT1-expression was observed in two unrelated patients
(from Japan and Saudi Arabia) with heterozygous missense mutations
in the STAT1 SH2 domain [168]. Further studies in both mice and
humans are required to fully unravel the role of IL-27 during anti-fungal
immunity.
3.4. IL-35
IL-35 is mainly produced by Bregs and Tregs [169]. Stimulation of
naïve eﬀector T cells with recombinant IL-35 suppressed T cell pro-
liferation in a murine model and ectopic expression of IL-35 on naïve T
cells conferred regulatory activity [71]. IL-35 has been shown to sup-
press immune responses important for the induction of inﬂammatory
disease in murine models such as collagen-induced arthritis [69,71].
However, human T regulatory cells do not express IL-35 and as result a
role for IL-35 in humans remains unclear [72]. As cytokine subunits are
shared between IL and 35, IL-12 and IL-27, mechanistic studies to de-
termine speciﬁc roles for IL-35 in the regulation of anti-fungal im-
munity are challenging.
Il12p35-/- mice have been shown to have lower fungal burden
during oral candidiasis. As IL-12p35 is a subunit of IL-35, it is possible
that IL-35 may play an important role in reducing tissue damage during
oral infection [29]. Recently, heat killed C. albicans was shown to
suppress LPS-induced IL-12p70 production in M2 macrophages due to
increased Ebi3 expression, a subunit of IL-35. Further, the authors de-
monstrated that C. albicans induced IL-35 production, which inhibited
an LPS-induced M2 (anti-inﬂammatory) to M1 (inﬂammatory) pheno-
type change in BMDMs, thereby supressing an inﬂammatory response.
These results demonstrate a possible mechanism for how C. albicans is
able to evade immune detection [23].
4. Conclusions
IL-12, IL-23, IL-27 and IL-35 are critical cytokines in innate and
adaptive immune responses against fungal infections. They are im-
portant in regulating T cell responses and exert their eﬀects on the Th1,
Th17 and Treg immune pathways of T cell diﬀerentiation. These cy-
tokines are important in regulating the development of inﬂammation
and disease progression. A better understanding of the IL-12 receptor
cytokine family, particularly the newer members (IL-27 and IL-35) is
invaluable to fully unravel the importance of targeting this family to
develop immunotherapies to help ﬁght fungal infections.
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